You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Tauvid ™ (flortaucipir F18 injection)
300-3700 MBq/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How much radiation does Tauvid™ (flortaucipir F 18) expose a patient to?
The effective radiation dose from a 370-MBq (10 mCi) dose of Tauvid (flortaucipir F 18) is 8.7 mSv. The organs with the highest radiation-absorbed doses were the upper intestinal wall, small intestines, and liver.
Following intravenous administration of flortaucipir F 18, the drug was distributed throughout the body with less than
10% of the injected F 18 radioactivity present in the blood by 5 minutes following administration, and
5% present in the blood by 10 minutes after administration.1
The estimated radiation-absorbed doses for an average adult weighing 70 kg from intravenous injection of flortaucipir F 18 are shown in Table 1. The organs with the highest radiation-absorbed doses were the
Table 1. Estimated Radiation Absorbed Dose After a Flortaucipir F 18 Injection1,2
|
Organ/Tissue |
Mean
Absorbed Dose Per Unit |
|
Adrenal glands |
14 |
|
Brain |
8 |
|
Breasts |
7 |
|
Gallbladder wall |
38 |
|
Lower large intestine wall |
35 |
|
Small intestine wall |
85 |
|
Stomach wall |
13 |
|
Upper large intestine wall |
96 |
|
Heart wall |
30 |
|
Kidneys |
40 |
|
Liver |
57 |
|
Lungs |
34 |
|
Muscle |
9 |
|
Ovaries |
21 |
|
Pancreas |
14 |
|
Red bone marrow |
10 |
|
Osteogenic cells |
12 |
|
Skin |
6 |
|
Spleen |
10 |
|
Testes |
7 |
|
Thymus gland |
9 |
|
Thyroid |
7 |
|
Urinary bladder wall |
38 |
|
Uterus |
18 |
|
Total body |
12 |
|
Effective dose (µSv/MBq)a |
a Assumed radiation weighting factor, wr (formerly defined as quality factor, Q), of 1 for conversion of absorbed dose (Gray or rads) to dose equivalent (Sieverts or rem) for F 18. To obtain radiation absorbed dose in rad/mCi from above table, multiply the dose in μGy/MBq by 0.0037 (eg, 14 μGy/MBq x 0.0037 = 0.0518 rad/mCi).
Effective Dose
The effective radiation dose resulting from a 370-MBq (10-mCi) dose of flortaucipir F 18 is 8.7 mSv in an adult.1
The use of a computed tomography (CT) scan to calculate attenuation correction for reconstruction of flortaucipir F 18 images, as done in positron emission tomography (PET)/CT imaging, will result in additional radiation exposure dependent on the settings used in the CT acquisition.1,2
Enclosed Prescribing Information
Tauvid™ (Flortaucipir F 18 injection) for intravenous use, Lilly
1. Tauvid [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: April 27, 2026